2426547-83-1
Chemical Structure
HYL001
- CAS No.: 2426547-83-1
- Formula:C21H18N4O
- Molecular Weight:342.39
InChIKey: STJSBQUPJDTPOW-UHFFFAOYSA-N
SMILES: OC1=CC2=C(C3=C(CCC4)N4N=C3C5=CC=CC(C)=N5)C=CN=C2C=C1
Biological Activity: HYL001 is an orally active, selective ALK4/ALK5 inhibitor with Kd values of 13 nM and 22.5 nM for ALK4 and ALK5, respectively. HYL001 inhibits GLS expression. HYL001 impairs glutamine metabolism, mitochondrial respiration, the TCA cycle, oxidative phosphorylation, ATP production, and redox balance, while selectively targeting mitochondria, disrupting mitochondrial structure, and inducing Apoptosis and ROS. HYL001 inhibits tumor growth and liver metastasis. HYL001 can be used in research on breast cancer, hepatocellular carcinoma, and microsatellite-stable colorectal cancer metastasis[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
HYL001 | 99.94% | HYL001 is an orally active, selective ALK4/ALK5 inhibitor with Kd values of 13 nM and 22.5 nM for ALK4 and ALK5, respectively. HYL001 inhibits GLS expression. HYL001 impairs glutamine metabolism, mitochondrial respiration, the TCA cycle, oxidative phosphorylation, ATP production, and redox balance, while selectively targeting mitochondria, disrupting mitochondrial structure, and inducing Apoptosis and ROS. HYL001 inhibits tumor growth and liver metastasis. HYL001 can be used in research on breast cancer, hepatocellular carcinoma, and microsatellite-stable colorectal cancer metastasis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zou W, et al. Targeting glutamine metabolism as a potential target for cancer treatment. Journal of experimental & clinical cancer research : CR. 2025 Jul 01;44(1):180.
- [2]. Wang Q, et al. A novel lonidamine derivative targeting mitochondria to eliminate cancer stem cells by blocking glutamine metabolism. Pharmacological research. 2023 Apr;190:106740.
- [3]. Fan Z, et al. Boosting oxidative stress with hydroxyethyl starch smart nanomedicines to eliminate cancer stem cells. Accounts of Materials Research. 2024 Oct 24;5(12):1558-70.
- [4]. De Los Santos-Jiménez J, et al. GLS and GLS2 Glutaminase Isoenzymes in the Antioxidant System of Cancer Cells. Antioxidants (Basel, Switzerland). 2024 Jun 20;13(6):745.
- [5]. Tauriello DVF, et al. New Potent Inhibitor of Transforming Growth Factor-Beta (TGFβ) Signaling that is Efficacious against Microsatellite Stable Colorectal Cancer Metastasis in Combination with Immune Checkpoint Therapy in Mice. ACS pharmacology & translational science. 2025 Jan 10;8(1):97-112.
- [6]. Wang Q, et al. Glutaminolysis inhibition boosts photodynamic therapy to eliminate cancer stem cells. Biomaterials. 2024 Apr;306:122497. [Content Brief]
- [7]. Tauriello DV, et al. HYL001, a new potent TGFβ signaling inhibitor that is efficacious against microsatellite stable CRC metastasis in combination with immune checkpoint therapy in mice. bioRxiv. 2024 May 14:2024-05.
